NXLNEXALIN TECHNOLOGY, INC.
Is Nexalin Technology struggling financially?
Yes, by its own account. Nexalin Technology told the SEC on 10 Jul 2026, in Form DEF 14A, that there is substantial doubt about its ability to continue as a going concern.
Going concern disclosed Jul 2026
13/100
Critical
- Sector
- Biotech/Pharma
- Market cap
- $7.3M
- Source filing
- DEF 14A 10 Jul 2026
- Balance sheet
- 30 Jun 2026
Cash runway
-
1month
If the burn speeds up
Empty by Jul 2026
-
2months
If it eases off
Empty by Aug 2026
Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.
Out of cashTwo years or more
The runway math
Cash and short-term investments
$1.0M
÷
Cash burned over the last 12 months
$10.2M
What Nexalin Technology told the SEC
…not qualified or modified as to uncertainty, audit scope or accounting principles, except that each report contained an explanatory paragraph relating to substantial doubt about the Company s ability to continue as a going concern. During the fiscal years ended December 31, 2025 and 2024 and through July 10, 2026, neither the Company nor anyone on its behalf consulted with Marcum or CBIZ regarding (i) the…
NEXALIN TECHNOLOGY, INC., Form DEF 14A, filed 10 Jul 2026.
Read the filing on SEC.govWhat this means
- Not a bankruptcy filing, and not a prediction.
- It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
- The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.
What else the numbers show
- 41.0% share-count increase The company issued stock. Each share now owns 29.1% less of the business than a year ago, before any change in the price.
- Cash burn is increasing It is spending 32% more cash per year than it was, so the runway above shortens even if nothing else changes.
Other Biotech/Pharma companies that filed the doubt
- PLUR Pluri $18.5M
- CRIS Curis $3.3M
- NTHI Neonc Technologies Holdings $121.3M
- VVOS Vivos Therapeutics $6.0M
- RANI Rani Therapeutics Holdings $122.7M
- FEED ENvue Medical $4.3M